388 doi: (Published 26 February 2025) Cite this as: BMJ 2025;388:e080679 Linked Editorial GLP-1 receptor agonists and suicidality Samantha B Shapiro, doctoral student1 2, Hui Yin, statistician1, Oriana Hoi Yun Yu, endocrinologist and associate professor2 3 4, Soham Rej, psychiatrist and associate professor5 6, Samy Suissa, professor1 2 7, Laurent Azoulay, professor1 2 8 1 Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada 2 Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada 3 Division of Endocrinology, Jewish General Hospital, Montreal, QC, Canada 4 Division of Endocrinology & Metabolism, McGill University, Montreal, QC, Canada 5 Department of Psychiatry, Jewish General Hospital, Montreal, QC, Canada 6 Department of Psychiatry, McGill University, Montreal, QC, Canada 7 Department of Medicine, McGill University, Montreal, QC, Canada 8 Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada Correspondence: L Azoulay laurent mcgill.ca (or @profLAzoulay on X) Accepted 24 January 2025 Abstract Objective To determine whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with an increased risk of suicidal ideation, self-harm, and suicide among patients with type 2 diabetes compared with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 (SGLT-2) inhibitors
Moreover, it is crucial to consider safety as a primary concern when using Quetiapine
Psychological well-being Successful weight loss can have a positive impact on mental health and overall well-being
95% CI, 3.563 to 2.335
About the author: Mary Genevieve Carty, MS, MHEd holds Masters degrees in Complementary and Integrative Health as well as Higher Education and is currently a doctoral student in Health Science at George Washington Universitys College of Medicine and Health Science
